Ligand Reports First Quarter 2024 Financial Results May 7, 2024 04:00PM
Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Mar 4, 2024 08:00AM
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results Feb 27, 2024 07:00AM
Ligand Partner Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa® Feb 22, 2024 04:01PM
Ligand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires Feb 16, 2024 08:00AM
View Older Stories

Feb 13, 2024 04:01PM Ligand to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
Feb 1, 2024 05:00PM Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan 5, 2024 04:30PM Ligand Pharma (LGND) Announces FDA Approval of ZELSUVMI
Jan 5, 2024 04:30PM U.S. Food and Drug Administration Approves ZELSUVMI™ as a First-in-Class Medication for the Treatment of Molluscum Contagiosum
Dec 12, 2023 12:01PM Ligand Pharma (LGND) Provides Update on Portfolio Progress and Recent Transactions; Introduces 2024 Guidance
Dec 12, 2023 12:01PM Ligand Holds Investor and Analyst Day; Provides Update on Portfolio Progress and Recent Transactions; Introduces 2024 Guidance
Dec 6, 2023 04:02PM Ligand to Host Investor and Analyst Day on December 12, 2023 in New York City
Nov 9, 2023 08:00AM OmniAb Reports Third Quarter 2023 Financial Results and Business Highlights
Nov 8, 2023 04:01PM Ligand Reports Third Quarter 2023 Financial Results
Nov 1, 2023 08:01AM Ligand Pharma (LGND) Acquires Royalty on Sanofi’s (SNY) TZIELD for $20 Million
Nov 1, 2023 08:00AM Ligand Acquires Royalty on Sanofi’s TZIELD® for $20 Million
Oct 25, 2023 04:01PM Ligand To Report Third Quarter 2023 Financial Results On November 8
Oct 18, 2023 08:01AM Ovid Therapeutics (OVID) and Ligand Pharmaceuticals (LGND) Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid’s Cash Runway into 2026
Oct 18, 2023 08:00AM Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid’s Cash Runway into 2026
Sep 27, 2023 09:02AM Ligand Pharma (LGND) Acquires Assets of Novan, Inc. for $12.2 Million
Sep 27, 2023 09:00AM Ligand Acquires Assets of Novan, Inc. for $12.2 Million
Sep 26, 2023 05:06PM Ligand Pharma (LGND) Appoints Martine Zimmermann to its Board
Sep 26, 2023 05:05PM Ligand Appoints Martine Zimmermann to its Board of Directors
Sep 22, 2023 09:00AM Ligand’s Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and
Sep 21, 2023 09:21AM Travere Therapeutics (TVTX) Reports Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI
Sep 21, 2023 09:20AM Ligand’s Partner Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missi
Sep 18, 2023 05:20PM Ligand Pharma (LGND) to spin-out, merge Pelican with Primrose Bio; raises EPS outlook
Sep 18, 2023 05:17PM Ligand Spins Out and Merges Pelican Subsidiary with Primordial Genetics to Form Primrose Bio
Sep 1, 2023 10:02PM Ligand Pharmaceuticals Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Aug 10, 2023 04:05PM OmniAb Reports Second Quarter 2023 Financial Results and Business Highlights
Aug 8, 2023 04:01PM Ligand Reports Second Quarter 2023 Financial Results
Jul 27, 2023 01:30PM Ligand’s Collaborator Merck Announces V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3
Jul 25, 2023 04:30PM Ligand To Report Second Quarter 2023 Financial Results On August 8
Jul 17, 2023 09:00AM Ligand Pharma (LGND) Offers $15M to Acquire Assets of Novan (NOVN)
Jul 17, 2023 08:59AM Ligand Offers $15 Million to Acquire Assets of Novan, Inc.
May 16, 2023 07:30AM Ligand (LGND) Announces Viking Therapeutics Reports Positive Top-Line Results from Phase 2b VOYAGE Study of VK2809
May 16, 2023 07:30AM Ligand’s Partner Viking Therapeutics Announces Positive Top-Line Results from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
May 11, 2023 07:00AM OmniAb Reports First Quarter 2023 Financial Results and Business Highlights
May 4, 2023 04:01PM Ligand Reports First Quarter 2023 Financial Results
Apr 24, 2023 04:01PM Ligand to Report First Quarter 2023 Financial Results on May 4, 2023
Mar 30, 2023 04:05PM OmniAb Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
Mar 9, 2023 08:00AM Sermonix Pharmaceuticals Announces Initiation of Phase 3 ELAINE-3 Study of Lasofoxifene Plus Abemaciclib in Pre- and Post-Menopausal Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cance
Feb 22, 2023 04:01PM Ligand Reports Fourth Quarter and Full Year 2022 Financial Results
Feb 17, 2023 06:30PM Ligand’s Partner Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI™ (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephrop
Feb 6, 2023 04:01PM Ligand to Report Fourth Quarter Financial Results on February 22
Jan 6, 2023 08:05AM Ligand’s Partner Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum
Dec 13, 2022 08:41AM Ligand Pharma (LGND) introduces 2023 financial guidance
Dec 13, 2022 08:30AM Ligand Provides Highlights from its Investor and Analyst Day Event
Dec 5, 2022 07:04AM Ligand Pharma (LGND) Names Director Todd C. Davis as CEO
Dec 5, 2022 07:00AM Ligand Pharmaceuticals Names Director Todd C. Davis as CEO
Nov 15, 2022 07:00AM OmniAb Reports Third Quarter 2022 Financial Results and Business Highlights
Nov 7, 2022 04:01PM Ligand Reports Third Quarter 2022 Financial Results
Nov 1, 2022 04:01PM Ligand Announces Completion of OmniAb Spin-Off
Nov 1, 2022 04:01PM OmniAb Announces Completion of Spin-Off and Business Combination
Nov 1, 2022 08:00AM Ligand Distribution of OmniAb Complete and Business Combination Closed
View Older Stories